Basal-like breast cancer displays distinct patterns of promoter methylation

Cancer Biology and Therapy

Volumn 9, Issue 12, 2010, Pages 1017-1024

  Lee, Ji Shin ^a   Fackler, Mary Jo ^b   Lee, Jae Hyuk ^a   Choi, Chan ^a   Park, Min Ho ^a   Yoon, Jung Han ^a   Zhang, Zhe ^b   Sukumar, Saraswati ^b  

^a Chonnam National University Medical School   (South Korea)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basal like; Breast cancer; HER2; Luminal; Methylation; Quantitation

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN D2; CYTOKERATIN 5; CYTOKERATIN 6; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR TWIST;

ADULT; AGED; APC 1 GENE; ARTICLE; BRCA 1 GENE; BRCA 2 GENE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST CARCINOMA BASAL LIKE TYPE; BREAST CARCINOMA HER2 TYPE; BREAST CARCINOMA LUMINAL TYPE; CANCER CLASSIFICATION; CDH 1 GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYCLIN D2 GENE; DNA METHYLATION; ESR 1 GENE; GENE EXPRESSION; HIN 1 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KOREA; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; PROMOTER REGION; QUANTITATIVE ANALYSIS; RAR BETA GENE; RASSF 1A GENE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; TWIST GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; GENES, BRCA1; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 77954406621     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.12.11804     Document Type: Article

References (38)

1. Ko SS, Korean Breast Cancer Society. Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996-2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol 2008; 98:318-23.
2. Reis-Filho JS, Lakhani SR. Breast cancer special types: why bother? J Pathol 2008; 216:394-8.
3. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005; 205:248-54.
4. Alizadeh AA, Ross DT, Perou CM, van de Rijn M. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 2001; 195:41-52. (Pubitemid 32899044)
5. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-74.
6. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100:8418-23.
7. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100:10393-8.
8. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6.
9. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10:5367-74.
10. nd ed. Philadelphia: WB Saunders 2001; 41-69.
11. Baylin SB, Chen WY. Aberrant gene silencing in tumor progression: implications for control of cancer. Cold Spring Harb Symp Quant Biol 2005; 70:427-33.
12. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; 1:4-11.
13. Risinger JI, Maxwell GL, Berchuck A, Barrett JC. Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers. Ann N Y Acad Sci 2003; 983:208-12. (Pubitemid 36399333)
14. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003; 103:153-60.
15. Gonzalgo ML, Yegnasubramanian S, Yan G, Rogers CG, Nicol TL, Nelson WG, et al. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin Cancer Res 2004; 10:7276-83. (Pubitemid 39487715)
16. Motoshita J, Oue N, Nakayama H, Kuraoka K, Aung PP, Taniyama K, et al. DNA methylation profiles of differentiated-type gastric carcinomas with distinct mucin phenotypes. Cancer Sci 2005; 96:474-9. (Pubitemid 41387299)
17. Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, Lobo F, et al. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 2007; 7:133.
18. Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, et al. Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res 2004; 10:5998-6005. (Pubitemid 39287504)
19. Lehmann U, Celikkaya G, Hasemeier B, Länger F, Kreipe H. Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res 2002; 62:6634-8. (Pubitemid 35364131)
20. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003; 107:970-5. (Pubitemid 37429839)
21. Tisserand P, Fouquet C, Barrois M, Gallou C, Dendale R, Stoppa-Lyonnet D, et al. Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors. Cancer Biol Ther 2003; 2:559-63.
22. Magdinier F, Ribieras S, Lenoir GM, Frappart L, Dante R. Downregulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region. Oncogene 1998; 17:3169-76. (Pubitemid 29020812)
23. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999; 18:1957-65. (Pubitemid 29150082)
24. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92:564-9.
25. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 2005; 91:179-86. (Pubitemid 40684930)
26. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26:2126-32.
27. Bertolo C, Guerrero D, Vicente F, Cordoba A, Esteller M, Ropero S, et al. Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. Am J Clin Pathol 2008; 130:414-24.
28. Chang YS, Chung JH, Shin DH, Chung KY, Kim YS, Chang J, et al. Retinoic acid receptor-beta expression in stage I non-small cell lung cancer and adjacent normal appearing bronchial epithelium. Yonsei Med J 2004; 45:435-42. (Pubitemid 39010701)
29. Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T, et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 2006; 12:3306-10.
30. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004; 64:4442-52.
31. Huang P, Woolson RF, O'Brien PC. A rank-based sample size method for multiple outcomes in clinical trials. Stat Med 2008; 27:3084-104.
32. Huang P, Tilley B, Woolson R, Lipsitz S. Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem. Biometrics 2005; 61:532-9.
33. Lee JS, Fackler MJ, Teo WW, Lee JH, Choi C, Park MH, et al. Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis. Cancer Biol Ther 2008; 7:1398-406.
34. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002; 21:5462-82.
35. Suijkerbuijk KP, Fackler MJ, Sukumar S, van Gils CH, van Laar T, van der Wall E, et al. Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol 2008; 19:1870-4.
36. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26:2568-81.
37. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005; 5:388-93. (Pubitemid 40932041)
38. Pal SK, Mortimer J. Triple-negative breast cancer: novel therapies and new directions. Maturitas 2009; 63:269-74.